This is true. In the biotech space the success of one company helps all other companies in the sector. Unfortunately, the reverse is also true.
I should mention that FTO is important in GBM. I would expect that there is a reasonable possibility that it would be synergistic with CAR-T treatments for this cancer type. Of course the only way to find out is run trials, but we already know that bisantrene is effective against GBM in vitro as a low dose FTO targeted agent.
This is true. In the biotech space the success of one company...
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
